(Q44740214)

5 December 2017

title

Generalizability of clinical trial results for generalized anxiety disorder to community samples (English)

1 reference

generalized anxiety disorder

5 December 2017

main subject

1 reference

Carlos Blanco

3

0 references

author name string

Nicolas Hoertel

1

1 reference

5 December 2017

Yann Le Strat

2

1 reference

5 December 2017

Pierre Lavaud

4

1 reference

5 December 2017

Caroline Dubertret

5

1 reference

5 December 2017

publication date

11 April 2012

1 reference

5 December 2017

published in

Depression and Anxiety

1 reference

5 December 2017

volume

29

1 reference

5 December 2017

issue

7

1 reference

5 December 2017

page(s)

614-620

1 reference

Associations between anxiety disorders and physical illness.

5 December 2017

cites work

1 reference

Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality?

21 January 2018

1 reference

Behavior change intervention research in community settings: how generalizable are the results?

21 January 2018

1 reference

Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial

21 January 2018

1 reference

Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

21 January 2018

1 reference

Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).

21 January 2018

1 reference

Methodological issues in current antipsychotic drug trials

21 January 2018

1 reference

Effect of study criteria on recruitment and generalizability of the results

21 January 2018

1 reference

Generalizability of clinical trials for alcohol dependence to community samples

21 January 2018

1 reference

Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research

21 January 2018

1 reference

Prevalence and predictors of research participant eligibility criteria in alcohol treatment outcome studies, 1970-98.

21 January 2018

1 reference

Generalizability of clinical trials for cannabis dependence to community samples

21 January 2018

1 reference

How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey.

21 January 2018

1 reference

Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis

21 January 2018

1 reference

Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy

21 January 2018

1 reference

A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies.

21 January 2018

1 reference

The case for practical clinical trials in psychiatry

21 January 2018

1 reference

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

21 January 2018

1 reference

The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample

21 January 2018

1 reference

The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

21 January 2018

1 reference

The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample

21 January 2018

1 reference

The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample

21 January 2018

1 reference

Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial

21 January 2018

1 reference

Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies

21 January 2018

1 reference

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

21 January 2018

1 reference

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder

21 January 2018

1 reference

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study

21 January 2018

1 reference

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

Implications of pain in generalized anxiety disorder: efficacy of duloxetine

21 January 2018

1 reference

Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians

21 January 2018

1 reference

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder

21 January 2018

1 reference

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

21 January 2018

1 reference

Anxiety management for persistent generalised anxiety.

21 January 2018

1 reference

21 January 2018

The Clinician's Illusion

1 reference

Predictors of patient entry into alcohol treatment after initial diagnosis

21 January 2018

1 reference

The nosologic relationship between generalized anxiety disorder and major depression

21 January 2018

1 reference

Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment

21 January 2018

1 reference

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

21 January 2018

1 reference

National Trends in Outpatient Psychotherapy

21 January 2018

1 reference

The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder

21 January 2018

1 reference

What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression

21 January 2018

1 reference

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

21 January 2018

1 reference

7 January 2021

The infrequency of "pure culture" diagnoses among the anxiety disorders.

1 reference

7 January 2021

Generalizability of Clinical Trial Results for Major Depression to Community Samples

1 reference

7 January 2021

The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population.

1 reference

7 January 2021

Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

1 reference

7 January 2021

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine

1 reference

7 January 2021

Estimation of symptom-free days in generalized anxiety disorder

1 reference

7 January 2021

Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.

1 reference

7 January 2021

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

7 January 2021

Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study

1 reference

7 January 2021

Generalised anxiety: a controlled treatment study

1 reference

7 January 2021

Cognitive restructuring treatment: a controlled trail with anxious patients

1 reference

7 January 2021

Behavioral treatment of generalized anxiety disorder

1 reference

7 January 2021

Pharmaco-epidemiology: what do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions?

1 reference

7 January 2021

Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder

1 reference

7 January 2021

Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder

1 reference

7 January 2021

Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.21937

1 reference

5 December 2017

1 reference